Advertisement

Table of contents

  1. Front Matter
    Pages i-xxxii
  2. Immunology

    1. Front Matter
      Pages 1-1
    2. AKT
      Timothy A. Yap, Johann S. de Bono
      Pages 3-12
    3. Ezra A. Bernstein, Yvonne Saenger
      Pages 13-20
    4. Jun Wang, Lieping Chen
      Pages 21-29
    5. David Kotlyar, Anthony Leonardi
      Pages 31-42
    6. John M. Timmerman
      Pages 43-55
    7. Gordon J. Freeman, Arlene Sharpe
      Pages 57-66
    8. James W. Hodge, Amanda L. Boehm, Renee N. Donahue
      Pages 67-76
    9. Paulina Chorobik, Joanna Bereta
      Pages 77-94
    10. Claudia Palena
      Pages 95-107
    11. Sherven Sharma, Minu K. Srivastava, Marni-Harris White, Dorthe Schaue, Maie St John, Gang Zhang et al.
      Pages 109-116
    12. Frederick J. Kohlhapp, Andrew Zloza
      Pages 117-129
    13. David Kotlyar
      Pages 131-142
    14. CEA
      Marion Hartley, John L. Marshall
      Pages 143-155
    15. Tasha Hughes, Howard L. Kaufman
      Pages 157-170
    16. Hannah E. Goyne, Martin Cannon
      Pages 171-181
    17. Eric S. Bradley, Douglas G. McNeel
      Pages 183-198
    18. Louis M. Weiner, Christina Wu
      Pages 199-208
    19. Tyler R. Simpson, James P. Allison
      Pages 209-228
    20. Phil Livingston, Govind Ragupathi
      Pages 229-241
    21. Jedd Wolchok, Adam Cohen, David Schaer
      Pages 243-250
    22. Glenn Dranoff, Kenneth F. May Jr.
      Pages 251-259
    23. Doug Schwartzentruber
      Pages 261-266
    24. Mary L. Disis, Megan M. O’Meara
      Pages 267-275
    25. Hatem H. Soliman
      Pages 277-284
    26. Ellen H. de Moll, Joanna Dong, Margeaux Oliva, Yvonne Saenger
      Pages 285-294
    27. Diwakar Davar, Leonard J. Appleman, John M. Kirkwood
      Pages 295-322
    28. Howard L. Kaufman, Benjamin Kelley, Eduardo Braun
      Pages 323-334
    29. Marc Pellegrini, Pamela Ohashi
      Pages 335-343
    30. Howard L. Kaufman, Neal Dharmadhikari
      Pages 345-359
    31. Amanda L. Marzo, Ryan T. Sowell
      Pages 361-368
    32. Rosanne Spolski, Warren J. Leonard
      Pages 369-374
    33. Joel C. Sunshine, Evan J. Lipson
      Pages 375-383
    34. Brendan D. Curti
      Pages 385-390
    35. Olivera Finn, Lixin Zhang
      Pages 391-398
    36. William Richard Childs, Jeremy M. Pantin
      Pages 399-408
    37. Albert DeLeo, Theresa L. Whiteside
      Pages 409-418
    38. PAP
      David E. Adelberg, William Dahut
      Pages 419-426
    39. Patrick M. Dillon, Craig L. Slingluff
      Pages 427-439
    40. Eric Lutz, Dung Le, Elizabeth Jaffee
      Pages 441-450
    41. PSA
      James L. Gulley
      Pages 451-458
    42. Mads Hald Andersen, Jürgen Becker
      Pages 459-466
    43. Luke Wojdyla, Mark Frakes, Kymberly Harrington, Amanda Stone, Neelu Puri
      Pages 467-477
    44. Beverly Teicher
      Pages 479-485
    45. Kian-Huat Lim
      Pages 487-494
    46. Kian-Huat Lim
      Pages 495-502
    47. Daniel R. Principe, Riley J. Mangan, Paul J. Grippo
      Pages 503-516
    48. Jong Chul Park, Michael. B. Atkins
      Pages 517-527
    49. Michael I. Nishimura, Amir A. Al-Khami, Shikhar Mehrotra, Thomas Wolfel
      Pages 529-536

About this book

Introduction

In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight.

The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.

Keywords

Anti-angiogenic Targets HER2/EGFR Targets Nuclear Receptors Hormone Receptors Heme

Editors and affiliations

  • John L. Marshall
    • 1
  1. 1.Division of Hematology & Oncology, Georgetown Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashingtonUSA

Bibliographic information